Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:LIMN NASDAQ:RNTX NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.13-0.9%$1.23$1.01▼$8.08$35.20M0.31629,650 shs348,912 shsLIMNLiminatus Pharma$0.17-31.1%$0.20$0.13▼$33.66$11.04MN/A18.29 million shs25.87 million shsRNTXRein Therapeutics$1.03-1.0%$1.35$0.95▼$2.21$88.96M1.421.51 million shs390,003 shsSNTISenti Biosciences$0.99+0.3%$0.95$0.77▼$3.88$30.65M2.09212,410 shs155,797 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-0.88%-0.88%-1.74%-28.03%-18.71%LIMNLiminatus Pharma-31.14%-5.89%-22.51%-26.03%+16,939,900.00%RNTXRein Therapeutics-0.96%-1.90%-45.21%-14.88%-46.91%SNTISenti Biosciences+0.28%-2.29%-13.43%+14.76%-69.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.13-0.9%$1.23$1.01▼$8.08$35.20M0.31629,650 shs348,912 shsLIMNLiminatus Pharma$0.17-31.1%$0.20$0.13▼$33.66$11.04MN/A18.29 million shs25.87 million shsRNTXRein Therapeutics$1.03-1.0%$1.35$0.95▼$2.21$88.96M1.421.51 million shs390,003 shsSNTISenti Biosciences$0.99+0.3%$0.95$0.77▼$3.88$30.65M2.09212,410 shs155,797 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-0.88%-0.88%-1.74%-28.03%-18.71%LIMNLiminatus Pharma-31.14%-5.89%-22.51%-26.03%+16,939,900.00%RNTXRein Therapeutics-0.96%-1.90%-45.21%-14.88%-46.91%SNTISenti Biosciences+0.28%-2.29%-13.43%+14.76%-69.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.25Hold$11.00873.45% UpsideLIMNLiminatus Pharma 1.00SellN/AN/ARNTXRein Therapeutics 2.00Hold$8.00676.70% UpsideSNTISenti Biosciences 2.80Moderate Buy$8.75786.61% UpsideCurrent Analyst Ratings BreakdownLatest LIMN, SNTI, BTAI, and RNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.004/21/2026SNTISenti Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $5.003/30/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.003/27/2026LIMNLiminatus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/17/2026BTAIBioXcel Therapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.003/9/2026BTAIBioXcel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/5/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$640K54.52N/AN/A($3.42) per share-0.33LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/A$0.06 per share18.19($0.39) per shareN/ASNTISenti Biosciences$20K1,537.10N/AN/A$0.08 per share12.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$69.90M-$5.75N/AN/AN/A-11,078.53%N/A-201.53%8/11/2026 (Estimated)LIMNLiminatus Pharma-$10.21M-$0.44N/AN/AN/AN/AN/A-299.79%N/ARNTXRein Therapeutics-$49.87M-$1.90N/AN/AN/AN/A-510.35%-68.14%N/ASNTISenti Biosciences-$61.44M-$1.92N/AN/AN/AN/A-532.05%-103.35%8/6/2026 (Estimated)Latest LIMN, SNTI, BTAI, and RNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325-$0.54-$0.0075-$0.54$0.38 million$0.21 million5/15/2026Q1 2026LIMNLiminatus PharmaN/A-$0.03N/A-$0.03N/AN/A5/15/2026Q1 2026RNTXRein Therapeutics-$0.49-$0.19+$0.30-$0.19N/AN/A5/14/2026Q1 2026SNTISenti Biosciences-$0.36-$0.14+$0.22-$0.14$0.02 million$0.02 million3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/27/2026Q4 2025SNTISenti Biosciences-$0.43-$0.53-$0.10-$0.53$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.620.82LIMNLiminatus PharmaN/A0.960.05RNTXRein TherapeuticsN/A0.400.70SNTISenti BiosciencesN/A1.041.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%LIMNLiminatus PharmaN/ARNTXRein Therapeutics90.89%SNTISenti Biosciences25.70%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics3.70%LIMNLiminatus PharmaN/ARNTXRein Therapeutics5.10%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9030.88 million29.74 millionNo DataLIMNLiminatus PharmaN/A44.88 millionN/AN/ARNTXRein Therapeutics985.54 million26.61 millionN/ASNTISenti Biosciences431.15 million30.17 millionNot OptionableLIMN, SNTI, BTAI, and RNTX HeadlinesRecent News About These CompaniesSenti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureMay 16, 2026 | tipranks.comSenti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 15, 2026 | americanbankingnews.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...May 14, 2026 | markets.businessinsider.comSenti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid LeukemiaMay 14, 2026 | quiverquant.comQSenti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal PhaseMay 14, 2026 | globenewswire.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical ProgramMay 14, 2026 | globenewswire.comSenti Biosciences Holdings Inc.May 13, 2026 | barrons.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | markets.businessinsider.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | globenewswire.comSenti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesApril 1, 2026 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateMarch 27, 2026 | globenewswire.comSenti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer ConferenceMarch 23, 2026 | globenewswire.comSenti Biosciences Amends Lease, Restructures GeneFab SubleaseMarch 19, 2026 | tipranks.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | tmcnet.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comSenti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care ConferenceFebruary 24, 2026 | quiverquant.comQSenti Biosciences to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 24, 2026 | globenewswire.comSenti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy DevelopmentFebruary 20, 2026 | globenewswire.comSenti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)February 11, 2026 | globenewswire.comSenti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026February 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIMN, SNTI, BTAI, and RNTX Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.13 -0.01 (-0.88%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.15 +0.02 (+1.42%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Liminatus Pharma NASDAQ:LIMN$0.17 -0.08 (-31.14%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.17 0.00 (-2.01%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Rein Therapeutics NASDAQ:RNTX$1.03 -0.01 (-0.96%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Senti Biosciences NASDAQ:SNTI$0.99 +0.00 (+0.28%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.98 -0.01 (-0.80%) As of 05/22/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
